RU2002130065A - COMPOSITION HAVING CONTRACEPTIVE ACTIVITY - Google Patents

COMPOSITION HAVING CONTRACEPTIVE ACTIVITY

Info

Publication number
RU2002130065A
RU2002130065A RU2002130065/15A RU2002130065A RU2002130065A RU 2002130065 A RU2002130065 A RU 2002130065A RU 2002130065/15 A RU2002130065/15 A RU 2002130065/15A RU 2002130065 A RU2002130065 A RU 2002130065A RU 2002130065 A RU2002130065 A RU 2002130065A
Authority
RU
Russia
Prior art keywords
composition
contraceptive activity
estrogen
formula
contraceptive
Prior art date
Application number
RU2002130065/15A
Other languages
Russian (ru)
Other versions
RU2238095C2 (en
Inventor
Владимир Маркович Ржезников
Лилия Евгеньевна Голубовская
Ольга Николаевна Минайлова
Галина Семеновна Гриненко
Всеволод Всеволодович Корхов
Елена Александровна Лесик
Мария Анатольевна Петросян
Original Assignee
Эндокринологический научный центр РАМН
Filing date
Publication date
Application filed by Эндокринологический научный центр РАМН filed Critical Эндокринологический научный центр РАМН
Priority to RU2002130065/15A priority Critical patent/RU2238095C2/en
Priority claimed from RU2002130065/15A external-priority patent/RU2238095C2/en
Publication of RU2002130065A publication Critical patent/RU2002130065A/en
Application granted granted Critical
Publication of RU2238095C2 publication Critical patent/RU2238095C2/en

Links

Claims (3)

1. Состав, обладающий контрацептивной активностью и отличающийся тем, что в качестве гестагена предлагается 3-бутират 6-метил-17α-7-ацетоксипрегна-4,6-диен-3β-ол-20-она формулы I, а в качестве эстрогена 3,17-диацетат 11β-нитрокси-17α-этинилэстра-1,3,5(10)-триен-3,9α,17β-триола формулы II1. A composition having contraceptive activity and characterized in that 3-butyrate 6-methyl-17α-7-acetoxypregn-4,6-dien-3β-ol-20-one of the formula I is proposed as a progestogen and 3 as an estrogen , 17-diacetate of 11β-nitroxy-17α-ethinyl estra-1,3,5 (10) -trien-3,9α, 17β-triol of formula II
Figure 00000001
Figure 00000001
Figure 00000002
Figure 00000002
 2. Состав по п.1, отличающийся тем, что соотношение гестаген/эстроген составляет 6:1.2. The composition according to claim 1, characterized in that the ratio of gestagen / estrogen is 6: 1. 3. Состав по пп.1 и 2, отличающийся тем, что он предназначен для орального применения.3. The composition according to claims 1 and 2, characterized in that it is intended for oral use.
RU2002130065/15A 2002-11-12 2002-11-12 Composition eliciting contraceptive activity RU2238095C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2002130065/15A RU2238095C2 (en) 2002-11-12 2002-11-12 Composition eliciting contraceptive activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2002130065/15A RU2238095C2 (en) 2002-11-12 2002-11-12 Composition eliciting contraceptive activity

Publications (2)

Publication Number Publication Date
RU2002130065A true RU2002130065A (en) 2004-06-10
RU2238095C2 RU2238095C2 (en) 2004-10-20

Family

ID=33537232

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002130065/15A RU2238095C2 (en) 2002-11-12 2002-11-12 Composition eliciting contraceptive activity

Country Status (1)

Country Link
RU (1) RU2238095C2 (en)

Similar Documents

Publication Publication Date Title
ES2602823T3 (en) Process for the preparation of drospirenone
EP1571153A3 (en) A process for the preparation of drospirenone
RU2010100334A (en) DERIVATIVE 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENA, ITS APPLICATION AND MEDICINES CONTAINING A DERIVATIVE
BRPI0512991A (en) use of a progestin, pharmaceutically useful kit adapted for daily oral administration, and method of contraception in a female of childbirth
CA2594171A1 (en) 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter
RU2002103883A (en) Oral Active Androgens
EA200600964A1 (en) PHARMACEUTICAL PREPARATION FOR CONTINUOUS HORMONAL TREATMENT DURING A LONGER LONGER THAN 21-4 DAYS, INCLUDING TWO ESTROGEN AND / OR PROGESTINE COMPOSITIONS
EA201200377A8 (en) METHOD OF ORAL CONTRACEPTION IN WOMEN, METHOD OF MANAGING UNDESIRABLE BLEEDING AND INTENDED FOR USE IN THESE METHODS
RU2009102772A (en) 18-METHYL-19-NORANDROST-4-EN-17, 17-SPIROESTER (18-METHYL-19-NOR-20-SPIROX-4-EN-3-OH) AND PHARMACEUTICALS THAT CONTAIN
CA2420292A1 (en) Contraception process and administration form for the same
EA200100108A1 (en) APPLICATION OF BIOGENAL SULFAMATS OF ESTROGENS FOR HORMONE-SUBSTITUTE THERAPY
RU99118008A (en) DERIVATIVES 16-HYDROXY-11- (SUBSTITUTED PHENYL) -ESTRA-4,9-DIENA
JP2010539153A5 (en)
RU2008138166A (en) COMPOSITION CONTAINING A COMBINATION OF AROMATASE INHIBITOR, PROGESTIN AND ESTROGEN, AND ITS APPLICATION FOR THE TREATMENT OF ENDOMETRIOSIS
RU2002130065A (en) COMPOSITION HAVING CONTRACEPTIVE ACTIVITY
CY1111406T1 (en) USE OF VALERIC OSTRADIOLIS OR OSTRADIOLIS IN COMBINATION WITH DIAGNOSTIC FOR ORAL TREATMENT OF BLOOD OSTRIPSI
EA200501739A1 (en) COMPOSITION CONTAINING PROTESTERONE RECEPTOR ANTAGONISTS AND PURE ANTIESTROGENS INTRODUCED FOR THE PREVENTION AND TREATMENT OF HORMONIZED DISEASES
RU2010100337A (en) 17β-CYANO-19-ANDROST-4-ENA DERIVATIVE, ITS APPLICATION AND MEDICINES THAT INCLUDE THE DERIVATIVE
EP1652526A3 (en) Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder
EP1535586A3 (en) Orthodontic microscrew
NO20072687L (en) Pharmaceutical contraceptive preparation
RU2220976C1 (en) 3-HYDROXYESTRA-1,3,5(10)-TRIENE-17-ONE OR β-ESTRA-1,3,5(10)-TRIENE-3,17-DIOL HIGHLY LABELED WITH TRITIUM
RU1789216C (en) Composition showing contraceptive effect
PL1937274T3 (en) Use of estradiol valerate combined with dienogest for oral therapy of dysfunctional uterine bleeding in the form of oral contraceptives
EA200300480A1 (en) APPLICATION OF ANTI-PROGESTINES FOR PREVENTION AND TREATMENT OF HORMONIZED DISEASES